AChR-blocking antibodies may help predict severity of myasthenia gravis
Acetylcholine receptor-blocking antibodies were linked to greater myasthenia gravis severity over time, unlike AChR-binding antibodies.
News
-
-
New analysis examines how older age affects response to MG treatment
Across 18 clinical trials of treatments for MG, older participants experienced smaller treatment-related improvements than younger patients.
-
New research explores why stress aggravates myasthenia gravis symptoms
MG symptoms worsened under chronic stress in a mouse study, highlighting the need for psychological support in MG.
-
Study examines the patient and environmental factors behind MG severity
Older age at onset, generalized symptoms, being underweight and having thymoma were linked to more severe MG.
-
Patients and providers explore technology’s role in rare disease care
Experts highlighted advances in genetic testing and AI while addressing ongoing barriers to equitable rare disease care.
-
Experts call for more research on the benefits of physical activity in MG
Though it’s not one-size-fits-all, exercise may help improve physical function and quality of life for people with myasthenia gravis.
-
Live antibody testing improves myasthenia gravis diagnosis
Live and fixed cell-based assays detected acetylcholine receptor antibodies more accurately than ELISA, particularly in ocular MG.
-
Autoimmune diseases may signal higher myasthenia gravis risk
People with myasthenia gravis were more likely to have another autoimmune disease in the 10 years before diagnosis.
-
Nipocalimab reduces hospital visits and costs in MG
Adding a treatment called nipocalimab to standard care lowered how much healthcare people needed and cut costs for adults with generalized MG.
-
People with MG face geographic gaps in access to neuromuscular specialists
The distribution of neuromuscular specialists in the United States remains unequal, leaving many people with MG with limited access to care
